Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and pathophysiology without original empirical data or systematic review methodology.
PubMed 31683709 · doi:10.3390/ijms20215444
What was done
Narrative review describing the etiology, metabolic reprogramming (including HIF-1α pathway activation, anoikis resistance, and glycolytic enzyme upregulation), and clinical management of cancer cachexia-anorexia syndrome (CAS) in patients with peritoneal metastasis from gastrointestinal and gynecological cancers.
What was found
The abstract reports no empirical numbers or quantitative data. It describes that peritoneal metastasis induces elevated resting energy expenditure, muscle mass loss, and chronic inflammation rather than simple starvation adaptation. It notes that HIF-1α upregulates key glycolytic enzymes and transporters (hexokinase II, PGK1, PDK, PKM2, LDH, GLUT) and promotes glutamine and fatty acid utilization. Total parenteral nutrition alone fails to reverse CAS, whereas pressurized intraperitoneal aerosol chemotherapy (PIPAC) was noted to stabilize nutritional status in a significant proportion of patients.
Why it matters
Synthesizes mechanistic understanding of why conventional caloric supplementation fails in peritoneal metastasis cachexia and highlights the need for targeted metabolic and locoregional therapies.
Limits
Narrative review design without systematic search methodology, meta-analysis, or new human empirical data. The abstract provides no sample sizes, effect sizes, or quantitative outcome measures.
Cited by
- supports In cancer cachexia, tumors stimulate protein mobilization from muscles to generate glucose via gluconeogenesis and directly consume glutamine.